Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical

Aging is the biggest risk factor for perturbation of the nervous system, even in the absence of distinct disease or trauma. For yet unknown reasons, the impulse conducting, myelinated projections and synaptic connections between nerve cells are especially vulnerable to aging-related degeneration. These pathological alterations often manifest as cognitive, sensory, and motor decline in older adults and represent a serious socio-economic challenge.

Malactivation leads to damage

Scientists have long assumed that inflammation plays an important role in this process. Mal-or overactivation of distinct belonging to the innate immune system—the microglia—appears to promote damage of nerve fibers and synapses in the aging central nervous system (CNS). In a recent project, scientists of the University Hospital Würzburg have now discovered an important role of the adaptive immune system.

Read more | >

Genetic treatments are difficult to produce without facilities.

Af­ter Kel­li Lug­in­buhl fin­ished her PhD, her ad­vi­sor, Duke bio­engi­neer and Phase­Bio co-founder Ashutosh Chilkoti, sat her down and asked if she want­ed to launch and then run a com­pa­ny. Chilkoti had a once-ob­scure tech­nol­o­gy he and the ven­ture cap­i­tal­ist Joe McMa­hon thought could form the ba­sis of his sec­ond com­pa­ny and fi­nal­ly pay huge div­i­dends. Lug­in­buhl knew the tech from years in his lab and was al­ready look­ing for biotech jobs. It all added up.

Three years, some strate­giz­ing, and 10 or so pitch meet­ings lat­er, the trio is launch­ing Isol­ere Bio, with $7 mil­lion in seed fund­ing led by North­pond Ven­tures and tech­nol­o­gy they be­lieve can al­low gene ther­a­py com­pa­nies to vast­ly in­crease the num­ber of dos­es they can pro­duce. It’s one po­ten­tial so­lu­tion to a slow-boil­ing cri­sis that has be­come in­creas­ing­ly acute, as new com­pa­nies strug­gle to get the ma­te­ri­als they need for tri­als and some com­mon dis­eases re­main the­o­ret­i­cal­ly un­fix­able by gene ther­a­py, be­cause com­pa­nies would nev­er be able to make enough dos­es for that many patients.

The prob­lem is par­tial­ly that the fa­cil­i­ties don’t yet ex­ist to pro­duce this much of gene ther­a­py. Ex­perts, how­ev­er, al­so point to an­ti­quat­ed man­u­fac­tur­ing processes.

Read more | >

In diabetic nephropathy—a common cause of kidney disease—levels of NEDD4-2 are severely reduced. This is the case even when salt is not a factor.

University of South Australia researchers have identified an enzyme that may help to curb chronic kidney disease, which affects approximately 700 million people worldwide.

This enzyme, NEDD4-2, is critical for kidney health, says UniSA Centre for Cancer Biology scientist Dr. Jantina Manning in a new paper published this month in Cell Death & Disease.

The early career researcher and her colleagues, including 2020 SA Scientist of the Year Professor Sharad Kumar, have shown in an animal study the correlation between a high salt , low levels of NEDD4-2 and advanced kidney .

Read more | >

After a decade of fighting for regulatory approval and public acceptance, a biotechnology firm has released genetically engineered mosquitoes into the open air in the United States for the first time. The experiment, launched this week in the Florida Keys — over the objections of some local critics — tests a method for suppressing populations of wild Aedes aegypti mosquitoes, which can carry diseases such as Zika, dengue, chikungunya and yellow fever.

Biotech firm Oxitec launches controversial field test of its insects in Florida after years of push-back from residents and regulatory complications.

Read more | >

LX1001, a gene therapy for Alzheimer’s disease being developed by Lexeo Therapeutics, has been granted fast track designation by the U.S. Food and Drug Administration (FDA).

The therapy is designed to deliver a version of the APOE gene, called APOE2, to cells in the central nervous system (the brain and spinal cord) using an engineered viral vector.

Every person inherits two copies of the APOE gene, one from each biological parent. There are three versions of the APOE gene, called alleles — APOE2, APOE3, and APOE4 (often abbreviated to E2, E3, and E4). The specific combination of alleles a person has affects their Alzheimer’s risk. Broadly, the E2 allele is associated with lower Alzheimer’s risk, whereas the E4 allele is linked to increased disease risk. As such, LX1001 is designed to deliver the protective allele (APOE2).

Read more | >

As founder of Longevity Vision Fund, I am often asked about the most promising life extension breakthroughs, from early cancer diagnostics to human avatars and everything in between. The simple answer is that there are many — but that’s probably not the kind of answer you were looking for!

Instead, let’s look at the latest longevity breakthroughs working on each of the five major levels of biological organization (cell, tissue, organ, organ system and organism) and what they each aim to accomplish.

Read more | >

In a study at The University of Alabama, aging fruit flies died faster than younger flies from a viral infection because of different genetic responses, lowering the older flies’ tolerance to the infection.

The findings published recently in G3: Genes, Genomes, Genetics add to the understanding of innate immunity, the first line of defense against infections, which is not fully understood in humans, and prove the fruit fly, Drosophila, is a good candidate for aging immunity studies that could lead to advancements in treating in older humans.

“We are living in times where there is a substantial increase in aging populations, and we know there is a decline of immune function in humans as we age,” said Dr. Stanislava Chtarbanova, UA assistant professor of biological sciences whose lab led the study. “This is the first study to use the fly for investigating age-dependent, anti-viral responses. Our lab can leverage this genetic model to study the underlying aging immunity.”

Read more | >